Lin, Rebecca and Muaadz, Asyraf and Ho, Gwo Fuang (2024) A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy. Gynecologic Oncology Reports, 51. ISSN 2352-5789, DOI https://doi.org/10.1016/j.gore.2024.101326.
Full text not available from this repository.Abstract
Uterine leiomyosarcomas (ULMS) are a rare cause of uterine malignancy. Due to their aggressive nature, resistance to standard therapy and high rates of recurrence, they are associated with a very poor prognosis, irrespective of their stage at diagnosis. A 68-year-old female, Chinese patient was diagnosed with Stage IVB uterine leiomyosarcoma with lung metastasis. Disease progression occurred after fourth-line treatment and the patient was commenced on pembrolizumab and temozolomide combination therapy. At the time of writing, our patient has experienced partial response to treatment with minimal adverse effects at cycle 7 of Pembrolizumab in combination with Temozolomide. © 2024 The Authors
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Combination therapy; Immunotherapy; Pembrolizumab; Refractory uterine leiomyosarcoma; Temzolomide; Uterine malignancy |
| Subjects: | R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine > Clinical Oncology Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 18 Jun 2024 01:37 |
| Last Modified: | 18 Jun 2024 01:37 |
| URI: | http://eprints.um.edu.my/id/eprint/44863 |
Actions (login required)
 |
View Item |
